Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial - The Lancet

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial  The Lancet

Comments

Popular posts from this blog

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows - News-Medical.Net